pharmaphorum
MARCH 22, 2022
Virtual and augmented reality tools have reached a level of maturity to be utilised across various industries. In this article, Ben Hargreaves asks whether there is particular potential for the technologies to revolutionise staff training and reduce costs in pharma manufacturing. Virtual reality (VR) and augmented reality (AR) have spent a lot of time in the headlines recently.
Pharma Times
MARCH 24, 2022
The platform to build a digital-ready frontline workforce will be available to all NHS and social care staff
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
MARCH 22, 2022
FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…. The post DrugPatentWatch Week in Review appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
MARCH 25, 2022
Members of a multidisciplinary care team may include physicians, nurses, pharmacists, radiologists, dieticians…the list goes on. But one key member is often omitted: the patient’s caregiver. With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. Although the caregiver is seen as an extension of the patient and their role is not strictly defined, they are informal members of the front-line care team.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 25, 2022
Tech giant Google has filed for FDA approval to use its Fitbit wearable to help detect atrial fibrillation (AFib), a common heart abnormality that raises the risk of heart attack, stroke and sudden death. Fitbit is already approved by the FDA to provide electrocardiogram (ECG) monitoring of heart rhythms, and in 2020 its Sense Smartwatch was cleared by the regulator to use the ECG functionality to detect AFib – although that requires active input from the user.
Pharma Times
MARCH 21, 2022
Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
NY Times
MARCH 23, 2022
The company said the vaccine produced a strong immune response in children younger than 6, but proved only about 40 percent effective in preventing symptomatic Covid-19.
pharmaphorum
MARCH 23, 2022
Four out of five biopharma companies think that the market opportunity for connected health products exceeds their traditional drug business, but adoption remains low, with only 20% of use cases at present going beyond proof of concept. That’s one of the conclusions of a new study by Capgemini, which suggests that the number of approved connected health offerings – digital health products and services including wearables, digital therapeutics and software-as-a-medical-device (SaMD) – will
Pharma Times
MARCH 25, 2022
The site in Kent will support the manufacture of regulatory approved cannabis-based medicines while also leveraging environmental practices
Outsourcing Pharma
MARCH 22, 2022
The agency has approved Lynparza for use in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
MARCH 21, 2022
Time for Drug Channels Institute’s annual update on the gross-to-net bubble —the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions. We estimate that the gross-to-net bubble reached $204 billion for patent-protected brand-name drugs in 2021. If we include brand-name drugs that have lost patent protection and face competition from generic equivalents, the bubble was even higher, at $236 billion.
pharmaphorum
MARCH 25, 2022
In January, PLOS Digital Health published a study which claimed that there’s “sparse” data to support the efficacy of most mental health apps. In their meta-analysis of published studies, the authors found universal deficiencies and concluded that there’s no convincing evidence that app-based interventions deliver meaningful outcomes. Without digging further, one might think the current case for digital therapeutics is weak.
Pharma Times
MARCH 24, 2022
Collaboration will focus on AI analysis of flu progression, immune responses and the development of new vaccines
Outsourcing Pharma
MARCH 24, 2022
The pharmaceutical company's clinical study is intended to examine critical gaps in care for people of color living with moderate to severe plaque psoriasis.
NY Times
MARCH 25, 2022
A drug to prevent preterm birth may provide the next test of the agency’s process for speedily getting drugs on the market, despite limited evidence that some work.
pharmaphorum
MARCH 24, 2022
Ann Aerts, head of the Novartis Foundation, tells us about AI4Leprosy, a diagnostic assistant researchers developed that helps healthcare workers detect leprosy with over 90% accuracy using pictures of a patient’s skin lesion. . Leprosy has existed for more than 3,000 years and is the one of the oldest diseases known to humanity. Though a cure is available, 200,000 individuals are still diagnosed with the disease each year. “We’ve managed to reduce the burden of leprosy by 95%
Pharma Times
MARCH 25, 2022
STP1 has demonstrated good safety and tolerability profiles, while also showing positive results for neurological function
Outsourcing Pharma
MARCH 25, 2022
The Pancreatic Cancer Action Network has engaged five new clinical trial sites in the US, which will aid in evaluation of Novartisâ investigational therapy.
Drug Channels
MARCH 25, 2022
Today’s guest post comes from Ian Ocilka, Senior VP of Client Solutions at ConnectiveRx. Ian explains some of the challenges associated with negotiating the medical benefit for both patients and providers. He goes on to describe the need for combining technology solutions and meaningful human connection for improved patient outcomes. To learn more, join experts from ConnectiveRx on April 26th at 1 pm ET for a free, online panel discussion: The Evolving Medical Benefits Landscape—Are you Ready fo
pharmaphorum
MARCH 23, 2022
Whether you’re a large pharma company or a small, emerging one, communication is key. Success or failure hinges on communicating the advantages of your offerings to both prescribing providers and patients. Join us on Tuesday 12 th April at 13:00 BST / 14:00 CET / 8:00 am EDT as panelists lay out how a better approach to communication can lead to improved patient outcomes, preventing drop-off rates, better predicting product forecasts, increasing script volume, integrating localised digital strat
Pharma Times
MARCH 23, 2022
Digital-first patient care is a priority as the companies join forces to improve patients' lives
Outsourcing Pharma
MARCH 24, 2022
The companyâs analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the countryâs borders.
Drug Patent Watch
MARCH 25, 2022
Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 25, 2022
The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for their Cabenuva product that does away with the need for an oral lead-in period. The label update means that people living with HIV who want to trade their daily oral doses of antiretroviral therapy (ART) for an injection delivered once a month or every two months will no long need to transition to oral therapy with the active ingredients in Cabenuva
Pharma Times
MARCH 22, 2022
Approval of Exkivity could mean NHS access to ground-breaking treatment for patients with rare lung cancer
Pharma in Brief
MARCH 23, 2022
The Federal Court ( FC ) has granted an application for judicial review involving the data protection provisions in section C.08.004.1 of the Food and Drug Regulations in a case involving new drug submissions ( NDSs ) for two different amifampridine products. This is the second time that the FC has set aside a decision to issue a notice of compliance ( NOC ) for the product in question on data protection grounds.
Drug Patent Watch
MARCH 25, 2022
Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are five patents protecting this drug. This drug has…. The post New patent for Deciphera Pharms drug QINLOCK appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 21, 2022
Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Exkivity (mobocertinib) as a monotherapy for non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR exon20 insertion mutations, after first-line chemotherapy.
Pharma Times
MARCH 22, 2022
Patients with a life-limiting skeletal condition welcome availability of elosulfase alfa on the NHS
PharmD Live
MARCH 23, 2022
If you’ve implemented chronic care management (CCM) or remote physiologic monitoring (RPM, a.k.a. remote patient monitoring) in your practice, you know that they generate new streams of revenue while allocating more time to take better care of your patients—with potentially life-saving results. In fact, Medicare is so confident that these programs will pay off that it has dramatically increased CCM overall reimbursement rates for 2022.
Drug Patent Watch
MARCH 25, 2022
Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. There are five patents protecting this drug. This drug has twenty-seven…. The post New patent for Strongbridge drug RECORLEV appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 23, 2022
It’s only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already has the positive data it was hoping for with etrasimod, the main asset in the deal. In its first phase 3 readout, oral S1P receptor modulator etrasimod met its objectives in patients with moderately-to-severely active ulcerative colitis, who had previously failed or were intolerant to at least one prior conventional, biological or JAK inhibitor therapy.
Pharma Times
MARCH 23, 2022
Groups including those aged over 75-years-old, care home residents and the immunocompromised will be entitled to a fourth jab
Pharma Marketing Network
MARCH 23, 2022
REGISTER HERE. Join PMN and industry marketing experts on April 28th at 12PM EST , to learn more about how to elevate your patient engagement marketing. Panels include: Effective Use of Data in DTC Marketing. There is no question that data is the path to better understanding your audience, but what data points are most important? What’s useful, and what’s misleading?
Drug Patent Watch
MARCH 23, 2022
Annual Drug Patent Expirations for SPIRIVA Spiriva is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. There are sixteen patents…. The post New patent expiration for Boehringer Ingelheim drug SPIRIVA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
131 
Let's personalize your content